Idiopathic Pulmonary Fibrosis Pipeline Insight

DelveInsight’s, “Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2021,” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Idiopathic Pulmonary Fibrosis Understanding

Idiopathic Pulmonary Fibrosis: Overview

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by chronic, progressive scarring of the lungs. The disease is caused when lung tissue becomes thick as well as stiff and eventually form scar tissue within the lungs. The two main symptoms of IPF are breathlessness and chronic cough. Risk factors for pulmonary fibrosis are age, sex, smoking, certain occupations, cancer treatments, and genetic factors. The diagnosis of idiopathic pulmonary fibrosis is based on the clinical, laboratory, radiologic, and/or pathologic data. Idiopathic Pulmonary Fibrosis treatment includes medicine, oxygen therapy, and/or pulmonary rehabilitation. Nintedanib and pirfenidone are approved medications to treat IPF. Medications for the treatment of IPF also includes chemotherapy drugs, heart medications, antibiotics, and/or anti-inflammatory drugs. Some people with IPF also go for lung transplant.


"Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Idiopathic Pulmonary Fibrosis pipeline landscape is provided which includes the disease overview and Idiopathic Pulmonary Fibrosis treatment guidelines. The assessment part of the report embraces, in depth Idiopathic Pulmonary Fibrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Idiopathic Pulmonary Fibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Idiopathic Pulmonary Fibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Idiopathic Pulmonary Fibrosis.

Idiopathic Pulmonary Fibrosis Emerging Drugs Chapters

This segment of the Idiopathic Pulmonary Fibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Idiopathic Pulmonary Fibrosis Emerging Drugs


Pamrevlumab: FibroGen

Pamrevlumab (FG-3019) is a fully recombinant human monoclonal antibody against connective tissue growth factor (CTGF). Pamrevlumab has been granted orphan drug and fast track designations by the U.S. Food and Drug Administration as a potential IPF treatment. Pamrevlumab is in Phase III clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.


C21: Vicore Pharma

C21 (VP01 program) is an orally available small molecule based non-peptide agonist of angiotensin II type 2 receptor. The drug is in clinical development for the treatment of IPF and COVID-19. C21 has been recognized as an orphan drug in IPF by the regulatory authorities in Europe and the USA.

Further product details are provided in the report……..

Idiopathic Pulmonary Fibrosis: Therapeutic Assessment

This segment of the report provides insights about the different Idiopathic Pulmonary Fibrosis drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Idiopathic Pulmonary Fibrosis

There are approx. 75+ key companies which are developing the therapies for Idiopathic Pulmonary Fibrosis. The companies which have their Idiopathic Pulmonary Fibrosis drug candidates in the most advanced stage, i.e. Phase III include, FibroGen.

Phases

DelveInsight’s report covers around 75+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Idiopathic Pulmonary Fibrosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Idiopathic Pulmonary Fibrosis therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Idiopathic Pulmonary Fibrosis drugs.

Idiopathic Pulmonary Fibrosis Report Insights

  • Idiopathic Pulmonary Fibrosis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Idiopathic Pulmonary Fibrosis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Idiopathic Pulmonary Fibrosis drugs?
  • How many Idiopathic Pulmonary Fibrosis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Idiopathic Pulmonary Fibrosis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Idiopathic Pulmonary Fibrosis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Idiopathic Pulmonary Fibrosis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Idiopathic Pulmonary Fibrosis: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Idiopathic Pulmonary Fibrosis – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Idiopathic Pulmonary Fibrosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Idiopathic Pulmonary Fibrosis Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Pamrevlumab: FibroGen

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

C21: Vicore Pharma

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

SM-04646: Biosplice Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

Pamapimod/pioglitazone: Kinarus

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Idiopathic Pulmonary Fibrosis Key Companies

Idiopathic Pulmonary Fibrosis Key Products

Idiopathic Pulmonary Fibrosis- Unmet Needs

Idiopathic Pulmonary Fibrosis- Market Drivers and Barriers

Idiopathic Pulmonary Fibrosis- Future Perspectives and Conclusion

Idiopathic Pulmonary Fibrosis Analyst Views

Idiopathic Pulmonary Fibrosis Key Companies

Appendix

List of Table

Table 1: Total Products for Idiopathic Pulmonary Fibrosis

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Idiopathic Pulmonary Fibrosis

Figure 2: Late Stage Products

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• FibroGen

• Vicore Pharma

• Boehringer Ingelheim

• AstraZeneca

• Avalyn Pharmaceuticals

• Indalo Therapeutics

• Biosplice Therapeutics

• Kinarus

• CohBar

• Reviva Biopharmaceuticals

• J2H Biotech

• Translate Bio

• Daewoong Pharmaceutical

• Roche

• Suzhou Zelgen Biopharmaceuticals

• Algernon Pharmaceuticals

• Pliant Therapeutics

• Galapagos NV

  • Tags:
  • Idiopathic Pulmonary Fibrosis Pipel...
  • Idiopathic Pulmonary Fibrosis clin...
  • Idiopathic Pulmonary Fibrosis comp...
  • Idiopathic Pulmonary Fibrosis drug...
  • Idiopathic Pulmonary Fibrosis ther...
  • Idiopathic Pulmonary Fibrosis trea...
  • Idiopathic Pulmonary Fibrosis pipe...
  • Idiopathic Pulmonary Fibrosis pipe...

Forward to Friend

Need A Quote